Abstract
The long and recently accelerated search for mechanisms of actions of drugs with psychotomimetic effects has utilized a broad array of classic pharmacologic and structure activity approaches (Cerletti and Doepfner, 1958; Hofmann, 1968), as well as quantitative structure activity relationships linked to molecular and submolecular properties (Barnett, et al., 1978). Behavioral and psychopharmacologic studies in man (Hollister, 1968; Freedman, 1968) and animal (Appel, 1968; Cameron and Appel, 1973; Jacobs et al., 1977) have appeared. Also utilized have been the techniques of neurophysiology (Brawley and Duffield, 1972; Aghajanian and Wang, 1978; Jacobs and Trulson, 1979); and biochemical pharmacology (Giarman and Freedman, 1965; Brimblecombe, 1973; Freedman and Halaris, 1978) as applied to CNS neurons. Central to this research has been a focus on d-lysergic acid diethylamide (LSD) because of the specificity, high potency, and reliability with which the drug produces a time-limited period of altered mental functioning. Approximately a billionth of a gram of LSD per gram of brain produces a 10-h state in which there is a compelled enhanced attention to subjective experience, a vividness of perception and affectivity (which is labile), and a diminished control over attention to environmental input (to which there is an enhanced but variably sustained reactivity).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abramson, H.A., Sklarofsky, B., Baron, M.O., Fremont-Smith, N.: Lysergic acid diethylamide (LSD-25) antagonists. II. Development of tolerance in man to LSD-25 by prior administration of MLD-41 (1-methyl-d-lysergic acid diethylamide). Arch. Neurol. Psychiat. 79, 201–207 (1958)
Aghajanian, G.K., Bing, O.H.L.: Persistence of lysergic acid diethylamide in the plasma of human subjects. Clin. Pharmacol. Ther. 5, 611–614 (1964)
Aghajanian, G.K., Haigler, H.J., Bennett, J.L.: Amine receptors in CNS III. 5-hydroxytrypta- mine in brain. In: Handbook of Psychopharmacology, 6, ED. Iverson, L.L., Iversen, S.D., Snyder, S.H. (eds.), pp. 63–96 New York: Plenum Press 1975
Aghajanian, G.K., Wang, R.Y.: Physiology and pharmacology of central serotonergic neurons. In: Psychopharmacology: A generation of progress. Lipton, M.A., Dimascio, A., Killam, K.F. (eds.), pp. 171–183, New York: Raven Press 1978
Ahn, H.S., Makman, M.H.: Interaction of LSD and other hallucinogens with dopamine-sensitive adenylate cyclase in primate brain: regional differences. Brain Res. 162, 77–78 (1979)
Anden, N.E., Corrodi, H., Fuxe, K., Hokfelt, T.: Evidence for a central 5-hydroxy-tryptamine receptor stimulation by lysergic acid diethylamide. Brit. J. Pharmacol. 34, 1–7 (1968)
Anden, N.E., Corrodi, H., Fuxe, K.: Hallucinogenic drugs of the indolealkyamine type and central monoamine neurons. J. Pharmacol. Exp. Ther. 179, 236–249 (1971)
Anden, N.E., Corrodi, H., Fuxe, K.: Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine and dopamine -ß-hydroxylase inhibitors. J. Pharm. Pharmacol. 24, 177–182 (1972)
Anden, N.E., Corrodi, H., Fuxe, K., Meek, J.L.: Hallucinogenic phenylethylamines: inter-actions with serotonin turnover and receptors. Eur. J. Pharmacol. 25, 176–184 (1974)
Anderson, G.M., III, Braun, U., Nichols, D.E., Shulgin, A.: Absolute configuration and psychotomimetic activity. In: Quantitative structure activity relationships of analgesics, narcotic antagonists, and hallucinogens. Barnett,G., Trsic, M., Willette, R.E., (eds.), Washington, D.C.: U.S. Government Printing Office, NIDA Research Monograph 22 (1978) (Stock No. 017-024-00786-2; (pp. 8–15)
Appel, J.B., Freedman, D.X.: Chemically-induced alterations in the behavioral effects of LSD- 25. Biochem. Pharmacol. 13, 861–869 (1964)
Appel, J.B., Freedman, D.X.: The relative potencies of psychomimetic drugs. Life Sci. 4, 2181–2186 (1965)
Appel, J.B.: The effects of “psychotomimetic” drugs on animal behavior. In: Psychopharma- cology: A Review of Progress, 1957–1967. Efron D.H. (ed.) Washington, D.C.: U. S. Gov-ernment Printing Office 1968
Appel, J.B., Freedman, D.X.: Tolerance and cross-tolerance among psychotomimetic drugs. Psychopharmacology 13, 267–274 (1968)
Appel, J.B., Sheard, M.H., Freedman, D.X.: Alterations in the behavioral effects of LSD by mid-brain raphe lesions. Commun. Behav. Biol. (Part A) 5, 237–241 (1970a)
Appel, J.B., Lovell, R.A., Freedman, D.X.: Alterations in the behavioral effects of LSD by pre- treatment with p-chloro-phenylalanine and alpha-methyl-p-tyrosine. Pschopharmacology 18, 387–406 (1970b)
Apter, J.T.: Anaeptic action of lysergic acid diethylamide [LSD-25] against pentobarbital. Arch. Gen. Psychiatry 79, 711–715 (1958)
Axelrod, J., Brady, R.O., Witkop, B., Evarts, E.V.: The distribution and metabolism of lysergic acid diethylamide. Ann. N.Y. Acad. Sci. 66, 435–444 (1957)
Balestrieri, A., Fontanari, D.: Acquired and crossed tolerance to mescaline, LSD-25, and BOL- 148. Arch. Gen. Psychiatry 1, 279 (1959)
Baldessarini, R.J., Stramentinoli, G., Lipinski, J.F.: Methylation hypothesis. Arch. Gen. Psychiatry 36, 303–307 (1979)
Banerjee, S.P., Sharma, V.K., Kung, L.S.: B-adrenergic receptors in innervated and denervated skeletal muscle. Biochim. Biophysica Acta 470, 123–127 (1977)
Bapna, J.S., Dandiya, P.C., Kulkarni, S.L.: Dissociation of excitatory and hyperpyrexic effects of LSD in rats treated with a-methyl-tyrosine. Jpn. J. Pharmacol. 23, 735–737 (1973)
Barchas, J.D., Freedman, D.X.: Brain amines: response to physiological stress. Biochem. Pharmacol. 12, 1225 (1963)
Barnett, G., Trsic, M., Willette, R.E., EDS. QuaSAR: Quantitative Structure Activity Rela-tionships of Analgesics, Narcotic Antagonists, and Hallucinogens. Washington, D.C., U. S. Government Printing Office, NIDA Research Monograph 22 1978 (Stock No. 017-024-00786-2)
Beernink, K.D., Nelson, S.D., Mansour, T.E.: Effect of lysergic acid derivatives on the liver fluke, Fasciola hepatica. Int. J. Neuropharmacol. 2, 105–112 (1963)
Bennett, J.L., Aghajanian, G.K.: LSD binding to brain homogenates: possible relationship to serotonin receptors. Life Sci. 15, 1935–1944 (1974)
Bennett, J.P., Snyder, S.H.: Stereospecific binding of d-lysergic acid diethylamide (LSD) to brain membranes: relationship to serotonin receptors. Brain Res. 94, 523–544 (1975)
Bennett, J.P., Jr., Snyder, S.H.: Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. Molec. Pharmacol. 12, 373— 389 (1976)
Bennett, J.P., Jr., Salvatore, J.B., Bylund, C.B., Gillin, J.C., Wyatt, R.F., Snyder, S.H.: Neu-rotransmitter receptors in frontal cortex of schizophrenics. Arch. Gen. Psychiatry 36, 927–924 (1979)
Berridge, M.J., Prince, W.T.: The nature of the binding between LSD and a 5-HT receptor: a possible explanation for hallucinogenic activity. Brit. J. Pharmacol. 57, 269–278 (1974)
Bertino, J.R., Klee, G.D., Weintraub, M.D.: Cholinesterase, d-lysergic acid diethylamide, and 2-bromolysergic acid diethylamide. J Clin. Exp. Psychopathol. 20, 218–227 (1959)
Bock, E., Braestrup, C.: Regional distribution of the synaptic membrane proteins: synaptin, Dl, D2 and D3. J. Neurochem. 30, 1603–1607 (1978)
Bockaert, J., Premont, J., Glowinski, J., Thierry, A.M., Tassin, J.P.: Topographical distribution of dopaminergic innervation and of dopaminergic receptors in the rat striatum. II. Distribution and characteristics of dopamine adenylate cyclase. Interaction of LSD with dopaminergic receptors. Brain Res. 107, 303–315 (1976)
Boggan, W.O., Freedman, D.X., Appel, J.B.: p-chlorophenylalanine-induced alterations in the behavioral effects of 5-hydroxytryptophan. Psychopharmacology 33, 293–298 (1973)
Bourgoin, S., Faivre-Bauman, A., Benda, P., Glowinski, J., Hamon, M.: Plasma tryptophan and 5-HT metabolism in the CNS of the newborn rat. J. Neurochem. 23, 319–327 (1974)
Bourgoin, S., Artaud, F., Enjalbert, A., Hery, F., Glowinski, J., Hamon, M.: Acute changes in central serotonin metabolism induced by the blockade or stimulation of serotonergic re-ceptors during ontogenesis in the rat. J. Pharmacol. Exp. Ther. 202, 519–531 (1977)
Bowers, M.B., Freedman, D.X.: “Psychedelic” experiences in acute psychoses. Arch. Gen. Psychiatry 75, 240–248 (1966)
Bowers, M.B., Jr.: Serotonin (5-HT) systems in psychotic states. Psychopharmac. Commun. 1, 655–662 (1975)
Bradley, P.B., Elkes, J.: The effects of some drugs on the electrical activity of the brain. Brain 80, 77–117 (1957)
Bramwell, G.J., Goyne, T.: Responses of midbrain neurones to microion tophoretically applied 5-hydroxytryptamine: comparison with the response to intravenously administered lysergic acid diethylamide. Neuropharmacology 15, 457–461 (1976)
Brawley, P., Duffield, J.C.: The pharmacology of hallucinogens. Pharmacol. Rev. 24, 31–66 (1972)
Brimblecombe, R.W.: Psychotomimetic drugs: biochemistry and pharmacology. In: Advances in drug research. Simmonds, A.B., (ed.), pp. 165–206, Vol. VII, London: Academic Press
Brimblecombe, R.W, Pinder, R.M.: Hallucinogenic agents. Bristol: Wright-Scientechnica
Brown, W.A., Krieger, D.T., van Woert, M.H., Ambani, L.M.: Dissociation of growth hormone and Cortisol release following apomorphine. J. Clin. Endocrin. 38, 1127–1129 (1974)
Brunelli, M., Castellucci, V., Kandel, E.R.: Synaptic facilitation and behavioral sensitization in aplysia: possible role of serotonin and cyclic AMP. Science 194, 1178–1180 (1976)
Burki, H.R., Asper, H., Ruch, W., Zuger, P.B.: Bromocriptine, dihydroergotoxine, methyser- gide, LSD, CF 25–397, and 29–712: effects on the metabolism of the biogenic amines in the brain of the rat. Psychopharmacology 57, 227–337 (1978)
Burt, D.R., Creese, I., Snyder, S.H.: Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196, 326–328 (1976a)
Burt, D.R., Creese, I., Snyder, S.H.: Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain. Molec. Pharmacol. 12, 631–638 (1976b)
Burt, D.R., Creese, I. Snyder, S.H.: Properties of (3H) haloperidol and (3H) dopamine binding associated with dopamine receptors in calf brain membranes. Molec. Pharmacol. 12, 800- 812 (1976c)
Cameron, O.G., Appel, J.B.: A behavioral and pharmacological analysis of some discrim- able properties of LSD in rats. Psychopharmacology 33, 117–134 (1973)
Carnegie, P.R.: Interaction of 5-hydroxytryptamine with the encephalitogenic protein of myelin. In: The Neurosciences: Third Study Program. Schmitt, F.O., Worden, F.G. (eds.), pp. 925–928, Cambridge: MIT Press 1972
Cerletti, A., Doepfner, W.: Comparative study on the serotonin antagonism of amide derivatives of lysergic acid and of ergot alkaloids. J. Pharmacol. Exp. Ther. 188, 124–136 (1958)
Charalampous, K.D., Walker, K.E., Kinross-Wright, J.: Metabolic fate of mescaline in man. Psychopharmacology 9, 48–63 (1966)
Chase, T.N., Breese, G.R., Kopin, I.J.: Serotonin release from brain slices by electrical stimulation: regional differences and effect of LSD. Science 157, 1461–1463 (1967)
Chiu, T.H., Lapa, A.J., Barnard, E.A., Albuquerque, E.X.: Binding of d-Tubocurarine and a- Bungarotoxin in normal and denervated mouse muscles. Exp. Neurol. 43, 399–413 (1974)
Christian, S.T., Harrison, R., Pagel, J.: Evidence for dimethyltryptamine (DMT) as a naturally- occurring transmitter in mammalian brain. Ala. J. Med. Sci. 13, 162–165 (1976)
Christian, S.T., Harrison, R., Quayle, E., Pagel, J., Monti, J.: The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent. Biochem. Med. 18, 164–183 (1977)
Christoph, G.R., Kuhn, D.M., Jacobs, B.L.: Dopamine Agonist pretreatment alters LSD’s electrophysiological action from dopamine agonist to antagonist. Life Sci. 23, 2099–2110 (1978)
Clark, L.D., Bliss, E.L.: Psychopharmacological studies of lysergic acid diethylamide (LSD-25) intoxication. Effects of premedication with BOL-148 (2-bromo-d-lysergic acid deithyla- mide), mescaline, atropine, amobarbital, and chlorpromazine. Arch. Neurol. Psychiat. 78, 653–655 (1957)
Collins, B.J., Lovell, R.A., Boggan, W.O., Freedman, D.X.: Effects of hallucinogens on rat brain monoamine oxidase activity. Pharmacologist 12, 256 (1970)
Consroe, P., Jones, B., Martin, P.: Lysergic acid diethylamide antagonism by chlorpromazine, haloperidol, diazepam, and pentobarbital in the rabbit. Toxicol. Appl. Pharmacol. 42, 45- 54 (1977)
Costa, E.: Effects of hallucinogenic and tranquilizing drugs on serotonin evoked uterine con-tractions. Proc. Soc. Exp. Biol. 91, 39–41 (1956)
Cottrell, G.A.: Direct postsynaptic responses to stimulation of serotonin-containing neurones. Nature 225, 1060–1062 (1970)
DaPrada, M., Saner, A., Burkard, W.P., Bartholini, G., Pletscher, A.: Lysergic acid diethylamide: Evidence for stimulation of cerebral dopamine receptors. Brain Res. 94, 67–73 (1975)
Davis, M., Sheard, M.H.: Habituation and sensitization of the rat startle response: effects of raphe lesions. Physiol. Behavior 72, 425–431 (1974)
de Montigny, C., Aghajanian, G.K.: Preferential action of 5-methoxytryptamine and 5- methoxydimethyltryptamine on presynaptic serotonin receptors: a comparative ionto- phoretic study with LSD and serotonin. Neuropharmacology 16, 811–818 (1977)
Diab, I.M., Roth, L.J., Freedman, D.X.: [3H] lysergic acid diethylamide: cellular audoradio- graphic localization in rat brain. Science 173, 1022–1024 (1971)
Diag, J.L., Huttunen, M.O.: Persistent increase in brain serotonin turnover after chronic administration of LSD in the rat. Science 174, 62–64 (1971)
Diaz, P.M., Ngai, S.H., Costa, E.: Factors modulating brain serotonin turnover. In: Advances in Pharmacology vol. 6B, pp. 75–92, New York, Academic Press 1968
DiPaolta, T., Hall, L.H., Kier, L.B.: Structure-activity studies on hallucinogenic amphetamines using model interaction calculations. J. Theor. Biol. 71, 295–309 (1978)
Dolphin, A., Enjalbert, A., Tassin, J., Lucas, M., Bockaert, J.: Direct interaction of LSD with central “beta”-adrenergic receptors. Life Sci. 22, 345–352 (1978)
Domino, E.F.: The indole hallucinogen model: Is it worth pursuing? In: Predictability in psy- chopharmacology. Preclinical and clinical correlations. Sudilovsky, A., Gershon, S., Beer, B. (eds.), pp. 247–268, New York: Raven Press 1975
Dyer, D.C., Gant, D.W.: Vasoconstriction produced by hallucinogens on isolated human and sheep umbilical vasculature. J. Pharmacol. Exp. Ther. 184, 366–375 (1973)
Elkes, J., Elkes, C., Bradley, P.B.: The effect of some drugs on the electrical activity of the brain and on behavior. J. Ment. Sci. 100, 125–141 (1954)
Enjalbert, A., Bourgoin, S., Hamon, M., Adrien, J., Bockaert, J.: Postsynaptic serotonin-sensitive adenylate cyclase in the central nervous system: I. Development and distribution of serotonin and dopamine-sensitive adenylate cyclases in rat and guinea pig brain. Molec. Pharmacol. 14, 2–10 (1978)
Enna, S.J., Bird, E.D., Bennett, J.P., Bylund, D.B., Yamamura, H.I., Iversen, L.I., Snyder, S.H.: Huntington’s chorea: changes in neurotransmitter receptors in the brain. New Engl. J. Med. 294, 1305–1309 (1976)
Fillion, G., Fillion, M.-P., Spirakis, C., Bahers, J.-M., Jacob, J.: 5-Hydroxytryptamine binding to synaptic membranes from rat brain. Life Sci. 18, 65–74 (1976)
Fillion, G.M.B., Rousselle, J.D., Fillion, M.P., Beaudoin, D.M., Goiny, M.R., Deniau, J.M., Jacob, J.J.: High affinity binding of [3H]5-hydroxytryptamine to brain synaptosomal membranes: comparison with [3H] lysergic acid diethylaminde binding. Molec. Pharmacol. 14, 50–59 (1978)
Fiszer, S., De Robertis, E.: Subcellular distribution and chemical nature of the receptor for 5- hydroxytryptamine in the central nervous system. J. Neurochem. 16, 1201–1209 (1969)
Freedman, D.X., Aghajanian, G.K., Ornitz, E.M., Rosner, B.S.: Patterns of tolerance to lysergic acid diethylamide and mescaline in rats. Science 127, 1173–1174 (1958)
Freedman, D.X., Aghajanian, G.L.: Time parameters in acute tolerance, cross tolerance, and antagonism to psychotogens. Fed. Proc. 18, 390 (1959)
Freedman, D.X.: Effects of LSD on brain serotonin. J. Pharmacol. Exp. Ther. 134, 160–166 (1961a)
Freedman, D.X.: Studies of LSD-25 and serotonin in the brain. Proc. 3rd World Congress of Psychiat. 7, 653 (1961b)
Freedman, D.X., Giarman, N.J.: LSD-25 and the status and level of brain serotonin. Ann. N.Y. Acad. Sci. 96, 98–106 (1962)
Freedman, D.X.: Psychotomimetic drugs and brain biogenic amines. Am. J. Psychiatr. 779, 843–850 (1963)
Freedman, D.X., Giarman, N.J.: Brain amines, electrical activity, and behavior. In: EEG and Behavior, (ed.) Glaser, G.H., pp. 198–243. New York: Basic Books 1963
Freedman, D.X., Effect of reserpine on plasma binding and brain uptake of LSD-25. Fed. Proc. 23, 147 (1964)
Freedman, D.X., Coquet, C.A.: Regional and subcellular distribution of LSD and effects on 5-HT levels. Pharmacologist 7, 183 (1965)
Freedman, D.X.: On the use and abuse of LSD. Arch. Gen. Psychiatr. 18, 330–347 (1968)
Freedman, D.X., Gottlieb, R., Lovell, R.A.: Psychotomimetic drugs and brain 5-hydroxytryp- tamine metabolism. Biochem. Pharmacol. 19, 1181–1188 (1970)
Freedman, D.X., Halaris, A.E.: The role of serotonin in the action of psychotomimetic drugs. (Abstract). Presented at 3rd Ann. Meeting Society for Neurosci. (1973)
Freedman, D.X., Boggan, W.O.: In: Serotonin - New Vistas: Histochemical and Pharmacology (Advances in Biochemical Psychopharmacology), Costa, E., Gessa, G.L., Sandler, M. (eds.), Vol. 10, pp. 151–157, New York: Raven Press 1974
Freedman, D.X., Halaris, A.E.: Monoamines and the biochemical mode of action of LSD at synapses. In: Psychopharmacology: A generation of progress, Lipton, M.S., Dimascio, A., Killam, K.F. (eds.), pp. 347–359, New York: Raven Press 1978
Freedman, D.X.: The mode of action of hallucinogenic drugs. In: Handbook of Biological Psychiatry. van Praag, Rafaelsen, Lader, Sacher (eds.), Vol. 2., New York: Marcel Dekker Inc. (in Press)
Fuxe, K., Fredholm, B.B., Ogren, S.O., Agnati, L.F., Hokfelt, T., Gustafsson, J.A.: Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis. Fed. Proc. 37, 2128–2191 (1978a)
Fuxe, K., Orgen, S.O., Aganti, L.F., Jonsson, G., Gustaffson, J.A.: 5,7-dihydroxytryptamine as a tool to study the functional role of central 5-hydroxytryptamine neurons. Ann. N.Y. Acad. Sci. 305, 346–369 (1978b)
Gaddum, J.H.: Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. J. Physiol. 121, 15 (1953)
Gaddum, J.H.: Serotonin-LSD interactions. Ann. N.Y. Acad. Sci. 66, 643–648 (1957)
Gerschenfeld, H.M.: Serotonin: Two different inhibitory actions on snail neurons. Science 777, 1252–1254 (1971)
Geyer, M.A., Dawsey, W.J., Mandell, A.J.: Fading: a new cytofluorimetric measure quantifying serotonin in the presence of catecholamines at the cellular level in brain. J. Pharmacol. Exp. Ther. 207, 650–667 (1978)
Giarman, N.J., Freedman, D.X.: Biochemical aspects of the actions of psychotomimetic drugs. Pharmacol. Rev. 77, 1–25 (1965)
Gillin, J.C., Kaplan, J., Stillman, R., Wyatt, R.J.: The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine. Am. J. Psychiat. 133, 203–208 (1976)
Goodwin, J.S., Katz, R.I., Kopin, I.J.: Effect of bromide on evoked release of monoamines from brain slices and intact atria. Nature 221, 556–557 (1969)
Green, J.P., Johnson, C.L., Weinstein, H., Kang, S., Chou, D.: Molecular determinants for in-teraction with the LSD receptor: biological studies and quantum chemical analysis. In: The psychopharmacology of hallucinogens. Willette, R.E., Stillman, R.C. (eds.), pp. 28–60, New York: Pergamon Press (1978a)
Green, J.P., Weinstein, H., Maayant, S.: Defining the histamine H2-receptor in brain: the interaction with LSD. In: Quantitative structure activity relationships of analgesics, narcotic antagonists, and hallucinogens. Barnett, G., Trsic, M., Willette, R.E. (eds.), pp. 38–59, Washington, D.C.: U.S. Government Printing Office, NIDA Research Monograph 22 1978b (Stock No. 017-024-00786-2)
Greenberg, D.A., U’Prichard, D.C., Snyder, S.H.: Alpha-noradrenergic receptor binding in mammalian brain: differential labeling of agonist and antagonist states. Life Sci. 19, 69–76 (1976)
Greiner, T., Burch, N.R., Edelbert, R.: Psychopathology and psychophysiology of minimal LSD-25 dosage. Arch. Neurol. Psychiat. 79, 208–210 (1958)
Guilbaud, G., Besson, J.M., Oliveras, J.L., Liebeskind, J.C.: Suppression by LSD of the inhibitory effect exerted by dorsal raphe stimulation on certain spinal cord interneurons in the cat. Brain Res. 61, 417–422 (1973)
Halaris, A.E., Lovell, R.A., Freedman, D.X.: Subcellular studies on the effect of LSD in rat brain serotonin. Soc. Neurosci, 2nd Annu. Meet. p. 114 (Abstr.) (1972)
Halaris, A.E., Lovell, R.A., Freedman, D.X.: Effect of chlorimipramine on the metabolism of 5-hydroxytryptamine in the rat brain. Biochem. Pharmacol. 22, 2200–2202 (1973)
Halaris, A.E., Freedman, D.X., Fang, V.S.: Plasma corticoids and brain tryptophan after acute and tolerance dosage of LSD. Life Sci. 17–1472 (1975)
Halaris, A.E., Freedman, D.X.: Vesicular and juxtavesicular serotonin: effects of lysergic acid diethylamide and reserpine. J. Pharmacol. Exp. Ther. 203, 575–586 (1977)
Hamilton, C.L.: Effects of LSD-25 and amphetamine on a running response in the rat. Arch. Gen. Psychiatry 2, 104–109 (1960)
Hamon, M., Bourgoin, S., Jagger, J., Glowinski, J.: Effects of LSD on synthesis and release of 5-HT in rat brain slices. Brain Res. 69, 265–280 (1974)
Hamon, M., Bourgoin, S., Enjalbert, A., Bockaert, J., Hery, F., Ternaux, J.P., Glowinski, J.: The effect of quipazine on 5-HT metabolism in the rat brain. Arch. Pharmacol. 294, 99–108 (1976)
Hashimoto, H., Hayashi, M. Nakahara, Y., Niwaguchi, T., Ishii, H.: Hyperthermic effects of d-lysergic acid diethylamide (LSD) and its derivatives in rabbits and rats. Arch. Int. Phar- macodyn. 228, 314–321 (1977)
Hendley, E., Snyder, S.H.: Correlation between psychotropic potency of psychotomimetic methoxyamphetamines and their inhibition of 3H-normetanephrine uptake in rat cerebral cortex. Nature 229, 264–266 (1971)
Hery, F., Simonnet, G., Bourgoin, S., Soubrie, P., Artaud, F., Hamon, M., Glowinski, J.: Effect of nerve activity on the in vivo release of [3H] serotonin continuously formed from L- [3H]tryptophan in the caudate nucleus of the cat. Brain Res. 169, 317–334 (1979)
Hofmann, A.: Psychotomimetic agents. In: Drugs affecting the central nervous system, Medical research series. Burger, A. (ed.), Vol.11, Chapter 5, pp. 169–236, New York: Marcel Dekker 1968
Hollister, L.E.: Some human pharmacological studies of three psychotropic drugs: thiothixine, molidone and w-1867. J. Clin. Pharmacol. 8, 95–101 (1968)
Hollister, L.E., Macnicol, M.F., Gillespie, H.K.: An hallucinogenic amphetamine analog (DOM) in man. Psychopharmacology 14, 62–73 (1969)
Horita, A.: Some biochemical studies on psilocybin and psilocin. J. Neuropsychiat. 4, 270–273 (1963)
Horita, A., Hamilton, A.E.: Lysergic acid diethylamide: dissociation of its behavioral and hy-perthermic actions of DL-a-methyl-p-tyrosine. Science 164, 78–79 (1969)
Horita, A., Hamilton, A.E.: The effects of DL-a-methyltyrosine and L-dopa on the hyperthermic and behavioral actions of LSD in rabbits. Neuropharmacology 12, 471–476 (1973)
Horowski, R., Wachtel, H.: Direct dopaminergic actions of lisuride hydrogen maleate, an ergot derivative in mice. Eur. J. Pharmacol. 36, 373–383 (1976)
Horowski, R.: Differences in the dopaminergic effects of the ergot derivatives bromocriptine, lisuride and LSD as compared with apomorphine. Eur. J. Pharmacol. 51, 157–166 (1978)
Hughes, J.: Inhibition of noradrenaline release by lysergic acid diethylamide. Brit. J. Pharmacol. 49, 706–708 (1973)
Isbell, H., Logan, C.R.: Studies on the diethylamide of lysergic acid (LSD-25). II. Effects of chlorpromazine, azacyclonol, and reserpine on the intensity of the LSD-reaction. Arch. Neurol. Psychiat. 77, 350–358 (1957)
Isbell, H., Logan, C.R., Miner, E.J.: Relationships of psychotomimetic to anti-serotonin potencies of congeners of lysergic acid diethylamide (LSD-25). Psychopharmacology 7, 20–28 (1959a)
Isbell, H., Miner, E.J., Logan, C.R.: Cross tolerance between d-2-Bromlysergic acid diethylamide (BOL-148) and d-diethylamide of lysergic acid (LSD-25). Psychopharmacology 7,109- 116 (1959b)
Isbell, H., Wolbach, A.B., Wikler, A., Miner, E.J.: Cross tolerance between LSD and psilocy- bin. Psychopharmacology 2, 147–159 (1964)
Jacobs, B.L., Trulson, M.E., Stern, W.C.: Behavioral effects of LSD in the cat: Proposal of an animal behavioral model for studying the actions of hallucinogenic drugs. Brain Res. 132, 301–314 (1977)
Jacobs, B.L., Trulson, M.E.: Mechanisms of action of LSD. Am. Sc. 67, 396–404 (1979)
Jonsson, G., Pollare, T., Hallman, H., Sachs, C.H.: Developmental plasticity of central serotonin neurons after 5,7-dihydroxytryptamine treatment. Ann. N.Y. Acad. Sci. 305, 328–345 (1978)
Kang, S., Green, J.P.: Steric and electronic relationships among some hallucionogenic compounds. Proc. Natl. Acad. Sci. USA 67, 62–67 (1970)
Katz, R.I., Kopin, I.J.: Effect of LSD and related compounds on release of norepinephrine-3H and serotonin-3H evoked from brain slices by electrical stimulation. Pharmacol. Res. Com- mun. 7, 54–62 (1969)
Kehr, W.: Effect of lisuride and other ergot derivatives on monoaminergic mechanisms in rat brain. Eur. J. Pharmacol. 41, 261–273 (1977)
Kehr, W., Speckenbach, W.: Effect of lisuride and LSD on monoamine synthesis after axotomy or reserpine treatment in rat brain. Naunyn-Schmiedeberg Arch. Pharmacol. 301, 163–169 (1978)
Keller, H.H., Burkhard, W.P., Lieri, L., Bonetti, E.P., DaPrada, M. Lisuride and LSD-induced changes of monoamine turnover in the rat brain. Adv. Biochem. Psychopharmacol. 19, 393–396 (1978)
Kier, L.B., Glennon, R.A.: Progress with several models for the study of the SAR of hallucinogenic agents. In: Quantitative structure activity relationships of analgesics, narcotic antagonists, and hallucinogens. Barnett, G., Trsic, M., Willette R.E. (eds.), pp. 149–185, Washington, D.C.: U.S. Government Printing Office, NIDA Research Monograph 22 1978 (Stock No. 017-024-00786-2)
Klein, M., Kandel, E.R.: Presynaptic modulation of voltage-dependent Ca2+ current: mecha-nism for behavioral sensitization of aplysia californica. Proc. Natl. Acad. Sci. U.S.A. 75, 3512–3516 (1978)
Koslow, S.H.: The biochemical and biobehavioral profile of 5-methoxytryptamine. In: Trace amines and the brain. Usdin, E., Sandler, M. (eds.), pp. 103–130, New York: Marcel Dekker 1976
Kosterlitz, H.W., Waterfield, A.A.: In vitro models in the study of structure-activity relationships of narcotic analgesics. Ann. Rev. Pharmacol. 15, 29–47 (1975)
Kovacic, B., Domino, E.F.: Tolerance and limited cross-tolerance to the effects of N, N-di- methyltryptamine (DMT) and lysergic acid diethylamide-25 (LSD) on food-rewarded bar pressing in the rat. J. Pharmacol. Exp. Ther. 197, 495–502 (1976)
Kräuchi, K., Feer, H., Lichtsteiner, M., Wirz-Justice, A.: Specific in vivo binding of LSD in rat brain. Experientia 34, 761–762 (1978)
Laduron, P.M., Janssen, P.F.M., Leysen, J.E.: Spiperone: ligand of choice for neuroleptic receptors. Biochem. Pharmacol. 27, 317–321 (1978)
Lin, R.C., Ngai, S.H., Costa, E.: Lysergic acid diethylamide: Role in conversion of plasma tryp-tophan to brain serotonin (5-hydroxy-tryptamine). Science 166, 237–239 (1969)
Lovell, R.A., Freedman, D.X.: Stereospecific receptor sites for d-lysergic acid diethylamide in rat brain: effects of neurotransmitters, amine antagonists and other psychotropic drugs. Molec. Pharmacol. 12, 620–630 (1976)
Mandell, A.J., Geyer, M.A.: Hallucinations: chemical and physiological. In: Biological foundations of psychiatry. Grenell, R.G., Gabay, S. (eds.), pp. 729–753, New York: Raven Press 1976
Mansour, T.E., Sutherland, E.W., Rail, T.W., Bueding, E.: The effect of serotonin (5-hydroxy- tryptamine) on the formation of adenosine 3’, 5’-Phosphate by tissue particles from the liver fluke, Fasciola hepatica. J. Biol. Chem. 235, 466–470 (1960)
Marchbanks, R.M.: Serotonin binding to nerve ending particles and other preparations from rat brain. J. Neurochem. 13, 1481–1493 (1966)
Marchbanks, R.M.: Inhibitory effects of lysergic acid derivatives and reserpine on 5-HT binding to nerve ending particles. Biochem. Pharmacol. 16, 1971–1979 (1967)
Marrazzi, A.S., Huang, C.C.: Qualitative identity of cerebral neuronal membrane actions of 5-HT, LSD, and CPZ. Biol. Psychiatry 14, 637–644 (1979)
Martin, W.R., Sloan, J.W.: Pharmacology and classification of LSD-like hallucinogens. In: Drug addiction. Martin, W.R. (ed.), pp. 305–368, Berlin-Heidelberg-New York: Springer Verlag 1977
Martin, W.R.: The nature of opioid and LSD receptors: structural activity relationship implications. In: Quantitative structure activity relationships of analgesics, narcotic antagonists, and hallucinogens. Barnett, G., Trsic, M., Willette, R.E., (eds.), pp. 60–69, Washington, D.C.: U. S. Government Printing Office, NIDA Research Monograph 22 1978 (Stock No. 017-024-00786-2)
McLean, J.R., McCartney, M.: Effect of d-amphetamine on rat brain noradrenaline and serotonin. Proc. Soc. Exp. Biol. Med. 107, 77–79 (1961)
Mehl, E., Weber, L.: Affinity chromatography for subfractionation of 5-hydroxytryptamine, LSD-binding proteins from cerebral and nerve ending membranes. Adv. Biochem. Psycho- pharmacol. 11, 105–108 (1974)
Mehl, E., Ruther, E., Redemann, J.: Endogenous ligands of a putative LSD-serotonin receptor in the cerebrospinal fluid: Higher level of LSD-displacing factors (LDF) in unmedicated psychotic patients. Psychopharmacology 54, 9–16 (1977)
Mehl, E., Guiard, L.: Physiological ligands of putative LSD-serotonin receptors: Heterogeneity of LSD-displacing factors in human body fluids and nervous tissue. Hoppe-Seyler’s Z. Physiol. Chem. 359, 539–542 (1978)
Meltzer, H.Y., Fessler, R.G., Simonovic, M., Doherty, J., Fang, V.S.: Lysergic acid diethylamide: evidence for stimulation of pituitary dopamine receptors. Psychopharmacology 54, 39- 44 (1977)
Menon, M.K., Clark, W.G., Masuoka, D.T.: Possible involvement of the central dopaminergic system in the antireserpine effect of LSD. Psychopharmacology 52, 291–297 (1977)
Muller, P., Seeman, P.: Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, a-noradrenergic and naloxone receptors. Life Sci. 21, 1751- 1758 (1977)
Murphree, H.B., DeMaar, E.W.J., Williams, H.L., Bryan, L.L.: Effects of lysergic acid derivatives on man: antogonism between d-lysergic acid diethylamide and its 2-brom congener. J. Pharmacol. Exp. Ther. 122, 55A (1958)
Nathanson, J.A., Greengard, P.: Serotonin-sensitive adenylate cyclase in neural tissue and its similarity to the serotonin receptor: a possible site of action of lysergic acid diethylamide. Proc. Natl. Acad. Sci. U.S.A. 71, 797–801 (1974)
Nichols, D.E.: Structural correlation between apmorphine and LSD: involvement of dopamine as well as serotonin in the actions of hallucinogens. J. Theor. Biol. 59, 167–177 (1976)
Nichols, D.E., Pfister, W.R., Yim, G.K.W.: LSD and phenethylamine hallucinogens: new structural analogy and implications for receptor geometry. Life Sci. 22, 2165–2170 (1978)
Niwaguchi, T., Inoue, T., Sakai, T.: Studies on the in vitro metabolism of compounds related to lysergic acid diethylamide (LSD). Biochem. Pharmacol. 23, 3063–3066 (1974)
Northup, J.K., Mansour, T.E.: Adenylate cyclase from Fasciola Hepatica: 2. Role of guanine nucleotides in coupling adenylate cyclase and serotonin receptors. Molec. Pharmacol. 14, 820–833 (1978)
Owen, F., Crow, T.J., Poulter, M., Cross, A.J., Longden, A., Riley, G.J.: Increased dopamine- receptor sensitivity in schizophrenia. Lancet 1978II, 223–225
Palmer, G.C., Burks, T.F.: Central and peripheral adrenergic blocking actions of LSD and BOL. Eur. J. Pharmacol. 16, 113–116 (1971)
Paul, S.M., Halaris, A.E., Freedman, D.X., Hsu, L.L.: Rat brain aryl acylamidase: stereospe- cific inhibition by LSD and serotonin related compounds. J. Neurochem. 27, 625–627 (1976)
Peroutka, S.J., Snyder, S.H.: Multiple serotonin receptors: differential binding of [3H]5-hy- droxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Molec. Pharmacol. 16, 687–699 (1979)
Persson, S.-A.: Effects of lysergic acid diethylamide (LSD) and 2-bromolysergic acid diethylamide (BOL) on central catecholaminergic pathways - A biochemical study. UMEA University Medical Dissertations No 32, University of Umea, Sweden (1977a)
Persson, S.-A.: The effect of LSD and 2-bromo LSD on the striatal dopa accumulation after decarboxylase inhibition in rats. Eur. J. Pharmacol. 43, 73–83 (1977b)
Persson, S.A., Johansson, H.: The effect of lysergic acid diethylamide (LSD) and 2-bromolyser- gic acid diethylamide (BOL) on the striatal dopa accumulation: influence of central 5-hy- droxytryptaminergic pathways. Brain Res. 142, 505–513 (1978)
Persson, S.-A.: Effects of LSD and BOL on the catecholamine synthesis and turnover in various brain regions. Psychopharmacology 59, 113–116 (1978)
Persson, T.: Drug induced changes in 3H-catecholamine accumulation after 3H-tyrosine. Acta Pharmacol. Toxicol. 28, 378–390 (1970)
Peters, D.A.V.: Comparison of the chronic and acute effects of d-lysergic acid diethylamide (LSD) treatment on rat brain serotonin and norepinephrin. Biochem. Pharmacol. 23, 231- 237 (1974a)
Peters, D.A.V.: Chronic lysergic acid diethylamide administration and serotonin turnover in various regions of rat brain. J. Neurochem. 23, 625–627 (1974b)
Peters, D.A.V., Tang, S.: Persistent effects of repeated injections of D-lysergic acid diethylamide on rat brain 5-hydroxytryptamine and 5-hydroxyindoleacetic acid levels. Biochem. Pharmacol. 26, 1085–1086 (1977)
Pieri, L., Pieri, M., Hafeley, W.: LSD as an agonist of dopamine receptors in the striatum. Nature 252, 586–588 (1974)
Pieri, M., Schaffner, R., Pieri, L., DaPrada, M., Hafeley, W.: Turning in MFG-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD. Life Sci. 22,1615— 1622 (1978a)
Pieri, L., Keller, H.H., Burkard, W., DaPrada, M.: Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 272, 278–280 (1978b)
Prozialeck,W.C., Vogel, W.H.: MAO inhibition and the effects of centrally administered LSD, serotonin, and 5-methoxy-tryptamine on the conditioned avoidance response in rats. Psychopharmacology 60, 309–310 (1979)
Purpura, D.: Electrophysiological analysis of psychotogenic drug action. I. Effect of LSD on specific systems in the cat. Arch. Neurol. Psychiat. 75, 122–131 (1956a)
Purpura, D.: Electrophysiological analysis of psychotogenic drug action. II. General nature of lysergic acid diethylamide (LSD) action on central synapses. Arch. Neurol. Psychiat. 75, 132–143 (1956b)
Ray, O.S., Marrazzi, A.S.: A quantifiable behavioral correlate of psychotogen and tranquilizer actions. Science 133, 1705–1706 (1961)
Resnick, O., Krus,D.M., Ruskin, M.: LSD-25 action in normal subjects treated with a monoamine oxidase inhibitor. Life Sci. 3, 1207–1214 (1964)
Rosecrans, J. A., Lovell, R.A., Freedman, D.X.: Effects of lysergic acid diethylamide on the me-tabolism of brain 5-hydroxytryptamine. Biochem. Pharmacol. 16, 2011–2021 (1967)
Rosenberg, D.E., Isbell, H., Miner, E.J.: Comparison of a placebo, N-dimethyltryptamine, and 6-hydroxy-N-dimethyltryptamine in man. Psychopharmacology 4, 39–42 (1963)
Rosenberg, D.E., Isbell, H., Miner, E.J., Logan, C.R.: The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacology 5, 217–227 (1964)
Sai-Halasz, A.: The effect of MAO inhibition of the experimental psychosis induced by di- methyltryptamine. Psychopharmacology 4, 385–388 (1963)
Schanberg, S.M., Giarman, N.J.: Drug-induced alterations in the subcellular distribution of 5- hydroxytryptamine in rat’s brain. Biochem. Pharmacol. 11, 187–194 (1962)
Schneckloth, R., Page, I.H., DelGreco, F., Corcoran, A.C.: Effects of serotonin antagonists in normal subjects and patients with carcinoid tumors. Circulation 16, 523–532 (1957)
Schubert, J., Nyback, H., Sedvall, G.: Accumulation and disappearance of 3H-5-hydroxytryp- tamine formed from 3H-tryptophan in mouse brain; effect of LSD-25. Eur. J. Pharmacol. 10, 215–224 (1970)
Seeman, P., Chau-Wang, M. Tedesio, J., and Wang, K.: Brain receptors for antipsychotic drugs and dysamine: Direct binding assays. Proc. Natl. Acad. Sci. U.S.A. 72, 4376–4380 (1975)
Seeman, P., Tedesco, J.L., Lee, T.; Chau-Wong, M., Muller, P., Bowles, J., Whitaker, P.M., McManus, C., Tittler, M., Weinreich, P., Friend, W.C., Brown, G.M.: Dopamine receptors in the central nervous system. Fed. Proc. 37, 130–136 (1978)
Shields, P.J., Eccleston, D.: Evidence for the synthesis and storage of 5-hydroxytryptamine in two separate pools in the brain. J. Neurochem. 20, 881–888 (1973)
Shulgin, A.T.: Psychotomimetic drugs: structure-activity relationships. In: Handbook of psy-chopharmacology. Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds.), pp. 243–333, Vol. II, New York: Plenum 1978
Shulgin, A.T., Sargent, T., Naranjo, C.: Structure-activity relationships of one-ring psychotomimetics. Nature 221, 537–541 (1969)
Shulgin, A.T., Sargent, T., Naranjo, C.: 4-Bromo-2,5-diemethoxyphenyl-isopropylamine, a new centrally active amphetamine analog. Pharmacology 5, 103–107 (1971)
Smith, R.C., Boggan, W.O., Freedman, D.X.: Effects of single and multiple dose LSD on endogenous levels of brain tyrosine and catecholamines. Psychopharmacology 42, 271–276 (1975)
Smythe, G.A.: The role of serotonin and dopamine in hypothalamic-pituitary function. Clin. Endocr. 7, 325–341 (1977)
Smythies, J.R., Johnson, V.S., Bradley, R.J.: Alteration by pretreatment with iproniazid and an inactive mescaline analogue for a behaviour change induced by mescaline. Nature 216, 196–197 (1967)
Snyder, S.H., Merril, C.R.: A relationship between the hallucinogenic activity of drugs and their electronic configuration. Proc. Natl. Acad. Sci. U.S.A. 54, 258–266 (1965)
Snyder, S.H., Reivich, M.: Regional localization of lysergic acid diethylamide in monkey brain. Nature 209, 1093–1095 (1966)
Snyder, S.H., Richelson, E.: Psychedelic drugs: steric factors that predict psychotropic activity. Proc. Natl. Acad. Sci. U.S.A. 60, 206–213 (1968)
Snyder, S.H., Weingartner, H., Faillace, L.A.: DOET (2,5-Dimethoxy-4-Ethylamphetamine), a new psychotropic drug: effects of varying doses in man. Arch. Gen. Psychiatry 24, 50 — 55 (1971)
Snyder, S.H.: Neurochemical actions of psychotropic drugs. Psychopharmacol. Bull. 11, 62 (1975a)
Snyder, S.H.: The opiate receptor. Neurosci. Res. Progr. Bull. 13, Suppl., 1–27 (1975b)
Soskin, R.A., Grof, S., Richards, W.A.: Low doses of dipropyltryptamine in psychotherapy. Arch. Gen. Psychiatry 28, 817–821 (1973)
Spano, P.F., Kumakura, K., Tonon, G.C., Govoni, S., Trabucchi, M.: LSD and dopamine-sen- sitive adenylate-cyclase in various rat brain areas. Brain Res. 93, 164–167 (1975)
Stolk, J.M., Barchas, J.D., Goldstein, M., Boggan, W.O., Freedman, D.X.: A comparison of psychotomimetic drug effects of rat brain norepinephrine metabolism. J. Pharmacol. Exp. Ther. 189, 42–50 (1974)
Sugrue, M.F.: A study of the role of noradrenaline in behavioral changes produced in the rat by psychotomimetic drugs. Br. J. Pharmacol. 35, 243–252 (1969)
Szara, S.: Dimethyltryptamine: its metabolism in man; the relation of its psychotic effects to the serotonin metabolism. Experientia 12, 441–442 (1956)
Szara, S., Hearst, E., Putney, F.: Metabolism and behavioral action of psychotropic tryptamine homologues. Int. J. Neuropharmacol. 1, 111–117 (1962)
Tamir, H., Klein, A., Rapport, M.M.: Serotonin binding protein: enhancement of binding by Fe2+ and inhibition of binding by drugs. J. Neurochem. 26, 871–878 (1976)
Thesleff, F.: Physiological effects of denervation of muscle. New York Acad. Sci. 228, 89–104 (1974)
Tilson, H.A., Sparber, S.B.: Studies on the concurrent behavioral and neurochemical effects of psychoactive drugs using the push-pull cannula. J. Pharmacol. Exp. Ther. 181, 387–398 (1972)
Tittler, M., Weinreich, P., Seeman, P.: New detection of brain dopamine receptors with [3H]di- hydroergocryptine(neuroleptics/ergots/ neurotransmitters/norepinephrine/schizophrenia). Proc. Natl. Acad. Sci. U.S.A. 74, 3750–3753 (1977)
Tonge, S.R., Leonard, B.E.: The effects of some hallucinogenic drugs upon the metabolism of 5-hydroxytryptamine in the brain. Life Sci. 8, 805–814 (1969)
Tonge, S.R., Leonard, B.E.: Hallucinogens and non-hallucinogens: a comparison of the effects on 5-hydroxytryptamine and noradrenaline. Life Sci. 10, 161–168 (1971)
Trulson, M.E., Eubanks, E.E., Jacobs, B.L.: Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5,7-dihydroxytryptamine. J. Phar- mac. Exp. Ther. 198, 23–32 (1976)
Trulson, M.E., Jacobs, B.L.: Usefulness of an animal behavioral model in studying the duration of action of LSD and the onset and duration of tolerance to LSD in the cat. Brain Res. 132, 315–326 (1977)
Trulson, M.E., Ross, C.A., Jacobs, B.L.: Lack of tolerance of the depression of raphe unit activity by lysergic acid diethylamide. Neuropharmacology 16, 771–774 (1977a)
Trulson, M.E., Stark, A., Jacobs, L.: Comparativeeffects of hallucinogenic drugs on rotational behavior in rats with unilateral 6-hydroxydopamine lesions. Eur. J. Pharmaol. 44, 113–119 (1977b)
Trulson, M.E., Jacobs, B.L.: Alterations of erotonin and LSD receptor binding following repeated administration of LSD. Life Sci. 24, 2053–2062 (1979a)
Trulson, M.E., Jacobs, B.L.: Dissociations between the effects of LSD on behavior and raphe unit activity in freely moving cats. Science 205, 515–518 (1979b)
Uzonov, P. Weiss, B.: Psychopharmacological agents in the cyclic AMP system of rat brain. In: Advances in Cyclic Nucleotide Research, Vol. I. Greengard, P., Paoletti, R., Robeson, G.A. (eds.), pp. 435–453. New York: Raven Press 1972
Van Loon, G.R., Scapagnini, V. Moberg, G.P., Ganong, W.F.: Evidence for central adrenergic neural inhibition of ACTH secretion in the rat. Endocrinology 89, 1464–1469 (1971)
Vaupel, D.B., Nozaki, M., Martin, W.R., Bright, L.D.: Single dose and cross tolerance studies of B-phenethylamine, d-amphetamine and LSD in the chronic spinal dog. Eur. J. Pharmacol. 48, 431–437 (1978)
von Hungen, K., Roberts, S., Hill, D.F.: LSD as an agonist and antagonist at central dopamine receptors. Nature 252, 588–589 (1974)
von Hungen, K., Roberts, S., Hill, D.F.: Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain. Brain Res. 94, 57–66 (1975)
Vrbanac, J.J., Tilson, H.A., Moore, K.E., Rech, R.H.: Comparison of 2,5-Dimethoxy-4- Methylamphetamine (DOM) and d-amphetamine for in vivo efflux of catecholamines from rat brain. Pharmacol. Biochem. Behav. 3, 57–64 (1975)
Wallach, M.B., Friedman, E., Gershon, S.: 2,5-Dimethoxy-4-methylamphetamine (DOM), a neuropharmacological examination. J. Pharmacol. Exp. Ther. 182, 145–154 (1972)
Wastek, G.J., Stern, L.Z., Johnson, P.C., Yamamura, H.I.: Huntington’s disease: regional alteration in muscarinic cholinergic receptor binding in human brain. Life Sci. 19, 1033–1040 (1976)
Weinstein, H., Green, J.P., Osman, R., Edwards, W.E.: Recognition and activation mech-anisms on the LSD/serotonin receptor: the molecular basis of structure activity relationships. In: Quantitative structure activity relationships of analgesics, narcotic antagonists, and hallucinogens. Barnett, G., Trsic, M., Willette, R.E. (eds.), pp. 333–35 Washington, D.C.: U.S. Government Printing Office, NIDA Research Monograph 22 1978 (Stock No. 017-024-00786-2
Whitaker, A.E., Lovell, R.A., Freedman, D.X.: Effect of chlorimipramine on the metabolism of 5-hydroxytryptamine in the rat brain. Biochem. Pharmacol. 22, 2200–2202 (1973)
Whitaker, P.M., Seeman, P.: Selective labelling of serotonin receptors by 3H-LSD in calf caudate. Proc. Natl. Acad. Sci. U.S.A. 75, 5783–5787 (1978)
Whitaker, P.M., Seeman, P.: Selective labelling of apomorphine receptors by 3H-LSD. Eur. J. Pharmacol. 56, 269–271 (1979)
Winters, J.C.: Tolerance to a behavioral effect of lysergic acid diethylamide and cross-tolerance to mescaline in the rat: absence of a metabolic component. J. Pharmacol. Exp. Ther. 178, 625–630 (1971)
Woolley, D.W., Shaw, E.: A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. U.S.A. 40, 228–231 (1954)
Wyatt, R.J., Cannon, E.H., Stoff, D.M., Gillin, J.C.: Interactions of hallucinogens at the clinical level. Ann. N.Y. Acad. Sci. 281, 456–486 (1976)
Ziegler, M.G., Lovell, R.A., Freedman, D.X.: Effects of lysergic acid diethylamide on the uptake and retention of brain 5-hydroxytryptamine in vivo and in vitro. Biochem. Pharmacol. 22, 2183–2193 ( 1973
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Freedman, D.X., Boggan, W.O. (1982). Biochemical Pharmacology of Psychotomimetics. In: Hoffmeister, F., Stille, G. (eds) Psychotropic Agents. Handbook of Experimental Pharmacology, vol 55 / 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67770-0_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-67770-0_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-67772-4
Online ISBN: 978-3-642-67770-0
eBook Packages: Springer Book Archive